Form 4: Theravance Biopharma Executive Reports Tax Withholding

Aine Miller, SVP of Development at Theravance Biopharma, reported the withholding of 6,827 shares to satisfy tax obligations related to RSU vesting.

Summary

• Aine Miller, SVP, Dev & Head of IRE Office at Theravance Biopharma, Inc. (TBPH), executed a transaction on May 20, 2026.
• The transaction involved the withholding of 6,827 ordinary shares by the issuer.
• The shares were withheld at a price of $16.55 per share to cover tax obligations resulting from the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person maintains a direct beneficial ownership of 177,334 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax obligation rather than a discretionary market trade.

Positives

• The transaction was a routine tax withholding event rather than an open market sale, indicating no change in the executive's long-term confidence in the company.

Negatives

• The transaction resulted in a reduction of the executive's total shareholdings by 6,827 shares.

Risks

• None identified; this is a standard administrative transaction related to equity compensation.

Future Outlook

Not applicable; this is a retrospective disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that tax withholding transactions are standard practice for biotechnology executives receiving equity-based compensation and do not typically signal shifts in corporate strategy or market sentiment.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for equity compensation management in the biopharmaceutical sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-market tax withholding event.

Next Steps

• None

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Trading, Equity Compensation, Tax Withholding